Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

Last updated: July 2, 2025
Sponsor: Beijing Chao Yang Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Respiratory Failure

Lung Injury

Acute Respiratory Distress Syndrome (Ards)

Treatment

Transpulmonary pressure

Clinical Study ID

NCT06062212
2023-KE-926
  • Ages 18-75
  • All Genders

Study Summary

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Meet the diagnostic criteria of Berlin's definition for ARDS;

  2. Receiving VV-ECMO support.

Exclusion

Exclusion Criteria:

  1. Patients had been on high pressure (Ppeak >35 cm H2O) and a high fraction ofinspired oxygen (FiO2>0.8) ventilation for >7 days;

  2. Patients had a contraindication to heparinization;

  3. Patients had an irreversible neurological injury;

  4. Patients had severe chronic lung disease with life expectancy <6 months.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Transpulmonary pressure
Phase:
Study Start date:
October 01, 2023
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Beijing Chao-Yang Hospital

    Beijing, Beijing 100020
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.